GeoVax Labs, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.5M | $4.0M | $0 | $81,526 | $385,501 |
| Research and development | $18.1M | $23.7M | $20.7M | $9.1M | $15.6M |
| Operating expenses | $24.1M | $29.1M | $26.7M | $14.1M | $19.1M |
| Operating income | -$21.6M | -$25.1M | -$26.7M | -$14.0M | -$18.7M |
| Interest expense | $0 | $21,375 | $0 | $0 | $1,286 |
| Income tax expense | — | — | — | — | $0 |
| Net income | -$21.5M | -$25.0M | -$26.0M | -$14.0M | -$18.6M |
| Balance Sheet | |||||
| Cash and equivalents | $3.1M | $5.5M | $6.5M | $27.6M | $11.4M |
| Current assets | $5.3M | $7.9M | $7.9M | $28.9M | $11.6M |
| Total assets | $6.3M | $8.2M | $9.3M | $31.3M | $11.8M |
| Current liabilities | $1.9M | $3.1M | $3.5M | $4.7M | $5.4M |
| Total liabilities | $2.5M | $3.1M | — | $4.7M | $7.4M |
| Stockholders' equity | $3.8M | $5.0M | $5.8M | $26.6M | $4.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$21.5M | -$24.7M | -$25.2M | -$19.0M | -$11.2M |
| Depreciation and amortization | $68,756 | $95,368 | $74,169 | $56,284 | $38,521 |
| Stock-based compensation | $1.1M | $528,644 | $1.1M | $902,074 | $369,987 |
| Capital expenditure | $27,612 | $20,653 | $48,946 | $134,258 | $47,718 |
| Free cash flow | -$21.5M | -$24.7M | -$25.2M | -$19.2M | -$11.2M |
| Share repurchases | — | — | — | — | $1,000 |
Shares outstanding 3.5M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.